BRCA2 and breast cancer: For BRCA1 heterozygotes, the largest association was seen with the ER-negative PRS313, while for BRCA2 heterozygotes, both the PRS313 and ER-positive PRS313 showed similar associations with contralateral breast cancer risk that were somewhat larger than the ER-negative PRS313 association.